Indeed, the reduced sensitivity of wild-type FLT3 to TKI treatment accompanied by the chemotherapy-dependent increase of FLT3 ligand promotes downstream proliferative pathways and AML progression. Here, FLT3 is linked to acute myeloid leukemia.